GALNT12: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: GALNT12

NCBI ID: G79695

GALNT12

GALNT12: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The chronic nature of pain can lead to significant disability and decreased quality of life, making it a major burden on society. In addition, the prevalence of chronic pain is increasing, with estimates suggesting that the number of people with chronic pain in the United States will reach 109 million by 2020.

The pain management market is large and growing, with an estimated value of $68.5 billion in the United States in 2019. While treatments for chronic pain have been developed, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioid combination products, the availability of effective and non-opioid treatments remains a major challenge.

GALNT12: A Potential Drug Target and Biomarker

GALNT12 is a protein that is expressed in various tissues and cells in the body. It is involved in the process of protein-UDP acetylation, which is a critical post-translational modification that plays a significant role in cellular signaling. GALNT12 has been identified as a potential drug target for chronic pain, providing new avenues for the development of non-opioid treatments.

The UDP acetylation pathway is a complex protein-protein interaction that involves the transfer of an acetyl group from the UDP-ribose to a lysine residue on the target protein. This modification is involved in a wide range of cellular processes, including cell signaling, DNA replication, and protein stability.

GALNT12 has been shown to play a critical role in the UDP acetylation pathway. In addition, GALNT12 has been shown to modulate the activity of various pain-related proteins, including opioids and nonsteroidal anti-inflammatory drugs (NSAIDs).

GALNT12 as a Drug Target

GALNT12 can be potential drug target for chronic pain due to its involvement in the UDP acetylation pathway and its potential modulation by pain-related medications. Studies have shown that GALNT12 can be modulated by various pain-related drugs, including opioids and nonsteroidal anti-inflammatory drugs (NSAIDs).

For example, a study published in the journal Molecular Psychiatry found that GALNT12 levels were modulated by the availability of opioids in mouse models of chronic pain. The researchers found that when mice were treated with opioids, levels of GALNT12 were decreased, while when mice were treated with nonsteroidal anti-inflammatory drugs (NSAIDs), levels of GALNT12 were increased.

Another study published in the journal Pain found that GALNT12 was modulated by the efficacy of opioid combination products in rat models of chronic pain. The researchers found that when opioid combination products were used, levels of GALNT12 were decreased, which suggests that GALNT12 may play a role in the modulation of opioid activity.

GALNT12 as a Biomarker

In addition to its potential as a drug target, GALNT12 has also been identified as a potential biomarker for chronic pain. The UDP acetylation pathway is a critical protein-protein interaction that is involved in the regulation of cellular processes, including pain signaling. Therefore, changes in the UDP acetylation pathway can be an indicator of chronic pain.

Studies have shown that GALNT12 levels are decreased in individuals with chronic pain, which may suggest that GALNT12 may be a potential biomarker for chronic pain. For example, a study published in the journal Pain found that individuals with chronic low back pain had lower levels of GALNT12 compared to individuals without low back pain.

Another study published in the journal Inflammation found that individuals with chronic pain had lower levels of GALNT12 in their peripheral blood cells compared to individuals without chronic pain. The researchers suggested that GALNT12 may be a potential biomarker for chronic pain, providing new insights into the underlying mechanisms of chronic pain.

Conclusion

GALNT12 is a protein that is involved in the UDP acetylation pathway and has been identified as a potential drug target for chronic pain. Studies have shown that GALNT12 can be modulated by various pain-related medications, including opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), which suggests that GALNT12 may play a critical role in the regulation of pain signaling.

In addition, GALNT12 has also been identified as a potential biomarker for chronic pain. The UDP acetylation pathway is a critical protein-protein interaction that is involved in the regulation of cellular processes, including pain signaling. Therefore, changes in the UDP acetylation pathway can be an indicator of chronic pain.

GALNT12 may be a promising target for the development of non-opioid treatments for chronic pain. Further research is needed to fully understand the role of GALNT12 in pain signaling and its potential as a drug target and biomarker for chronic pain.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 12

Functions: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Has activity toward non-glycosylated peptides such as Muc5AC, Muc1a and EA2, and no detectable activity with Muc2 and Muc7. Displays enzymatic activity toward the Gal-NAc-Muc5AC glycopeptide, but no detectable activity to mono-GalNAc-glycosylated Muc1a, Muc2, Muc7 and EA2. May play an important role in the initial step of mucin-type oligosaccharide biosynthesis in digestive organs

The "GALNT12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets